Brain Cancer Trial, Recruiting (NCT06118723)

Brain Cancer Trial, Recruiting NCT06118723 Sponsor: Jasper Gerritsen Condition: Brain Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06118723 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Brain Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 90 years old
People whose MRI scan has been assessed by a neurosurgeon and shows a high-grade brain tumour (classified as WHO grade III or IV)
People who are able to provide written agreement to take part in the trial

Who may not be able to join:

People whose tumour is located in the cerebellum, brainstem, or midline of the brain
People who have multiple tumour spots that show up with contrast dye on their scan
People who have a medical reason that prevents them from having an MRI scan (for example, having a pacemaker)
People who are unable to provide written agreement to take part in the trial
People whose high-grade brain tumour developed from a previously existing lower-grade brain tumour
People who have had another type of cancer in the past 5 years, except for certain skin cancers (basal cell carcinoma) or early-stage cancers confined to one organ that have been fully treated (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jasper Gerritsen, MD PhD, Erasmus Medical Center

Phone: +31107036130

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06118723

Sponsor: Jasper Gerritsen

Phase: Not Applicable

Status: Recruiting

Condition: Brain Cancer

Trial contact: +31107036130

More information: https://clinicaltrials.gov/study/NCT06118723

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 90 years old
People whose MRI scan has been assessed by a neurosurgeon and shows a high-grade brain tumour (classified as WHO grade III or IV)
People who are able to provide written agreement to take part in the trial

Who may not be able to join:

People whose tumour is located in the cerebellum, brainstem, or midline of the brain
People who have multiple tumour spots that show up with contrast dye on their scan
People who have a medical reason that prevents them from having an MRI scan (for example, having a pacemaker)
People who are unable to provide written agreement to take part in the trial
People whose high-grade brain tumour developed from a previously existing lower-grade brain tumour
People who have had another type of cancer in the past 5 years, except for certain skin cancers (basal cell carcinoma) or early-stage cancers confined to one organ that have been fully treated (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Jasper Gerritsen

Registry

ClinicalTrials.gov

Start date

1 January 2022

Est. completion

1 January 2027

Where this trial is recruiting

🇧🇪 Belgium 🇩🇪 Germany 🇳🇱 Netherlands 🇨🇭 Switzerland 🇺🇸 United States

Primary endpoints

Overall survival; Neurological morbidity at 6 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov